New patent expiration for Takeda Pharms drug VYVANSE
Annual Drug Patent Expirations for VYVANSE Vyvanse is a drug marketed by Takeda Pharms Usa and is included in two […]
New patent expiration for Takeda Pharms drug VYVANSE Read Post »
Patent Expiration
Drug Patent Expirations for the Week of August 20, 2023
VYVANSE (lisdexamfetamine dimesylate) Takeda pharms usa Patent: 7,718,619 Expiration: Aug 24, 2023 See More … For more information on how
Drug Patent Expirations for the Week of August 20, 2023 Read Post »
New patent expiration for Merz Pharms drug CUVPOSA
Annual Drug Patent Expirations for CUVPOSA Cuvposa is a drug marketed by Merz Pharms and is included in one NDA.
New patent expiration for Merz Pharms drug CUVPOSA Read Post »
New patent expiration for Bristol Myers drug ZERIT XR
Annual Drug Patent Expirations for ZERIT+XR Zerit Xr is a drug marketed by Bristol Myers Squibb and is included in
New patent expiration for Bristol Myers drug ZERIT XR Read Post »
Drug Patent Expirations for the Week of August 13, 2023
ZERIT XR (stavudine) Bristol myers squibb Patent: 7,135,465 Expiration: Aug 18, 2023 See More … For more information on how
Drug Patent Expirations for the Week of August 13, 2023 Read Post »
New patent expiration for Boehringer Ingelheim drug JENTADUETO
Annual Drug Patent Expirations for JENTADUETO Jentadueto is a drug marketed by Boehringer Ingelheim and is included in two NDAs.
New patent expiration for Boehringer Ingelheim drug JENTADUETO Read Post »
New patent expiration for Boehringer Ingelheim drug TRADJENTA
Annual Drug Patent Expirations for TRADJENTA Tradjenta is a drug marketed by Boehringer Ingelheim and is included in one NDA.
New patent expiration for Boehringer Ingelheim drug TRADJENTA Read Post »
New patent expiration for Boehringer Ingelheim drug TRIJARDY XR
Annual Drug Patent Expirations for TRIJARDY+XR Trijardy Xr is a drug marketed by Boehringer Ingelheim and is included in one
New patent expiration for Boehringer Ingelheim drug TRIJARDY XR Read Post »
New patent expiration for Boehringer Ingelheim drug GLYXAMBI
Annual Drug Patent Expirations for GLYXAMBI Glyxambi is a drug marketed by Boehringer Ingelheim and is included in one NDA.
New patent expiration for Boehringer Ingelheim drug GLYXAMBI Read Post »
